GlassScriptPhysician profile
Caitlin A Smith
NPI 1326445834
$2,480.43
in general payments reported to CMS, 2019-2025
34 companies · $793 in 2025
The $793 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.77 · 2022: $161 · 2023: $465 · 2024: $987 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $569.79 | 2022-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $286.72 | 2023-2025 | Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $212.85 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $160.28 | 2023-2025 | |
| Eisai INC. | $146.68 | 2022-2025 | |
| Glaxosmithkline, LLC. | $145.84 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Pfizer INC. | $116.31 | 2021-2025 | |
| Abbvie INC. | $116.18 | 2023-2024 | |
| Genmab U.S., INC. | $68.85 | 2022-2025 | Epkinly, Tivdak |
| Janssen Biotech, INC. | $68.03 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Lilly USA, LLC | $51.43 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $49.80 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Medtronic, INC. | $39.79 | 2024 | Plasmablade(Tm) |
| Philips North America LLC | $37.57 | 2025 | Event, Mcot |
| Agios Pharmaceuticals, INC. | $36.04 | 2025 | Pyrukynd |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.91 | 2024-2025 | |
| Amgen INC. | $30.03 | 2022-2023 | Lumakras |
| Biogen, INC. | $26.54 | 2021 | |
| Caris Mpi, INC. | $26.19 | 2025 | Mi Cancer Seek |
| Emmaus Medical, INC. | $21.33 | 2023 | Endari |
| Integra Lifesciences Corporation | $19.75 | 2021 | |
| Karyopharm Therapeutics INC. | $18.81 | 2023 | Xpovio |
| Deciphera Pharmaceuticals INC. | $18.72 | 2024 | Tgct, Qinlock |
| Helsinn Therapeutics (U.S.), INC. | $17.06 | 2025 | Akynzeo |
| Janssen Pharmaceuticals, INC | $16.99 | 2022 | |
| Pharmaessentia USA Corporation | $16.95 | 2024 | Besremi |
| Emd Serono, INC. | $16.88 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.81 | 2024 | Ultomiris |
| Stemline Therapeutics INC. | $16.55 | 2024 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2023 | Opdivo |
| Myriad Genetic Laboratories, INC. | $16.35 | 2023 | Myrisk |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Genentech USA, INC. | $14.75 | 2024 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Legend Biotech USA INC. | $13.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.